Company intelligence / Profile preview

Cancer InCITe

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Cancer InCITe is a precision medicine company focused on improving cancer treatment outcomes through advanced diagnostic and predictive modeling. The company's core technology, the InCITe platform, utilizes high-resolution imaging and spatial biology to analyze the tumor microenvironment and predict patient responses to specific immunotherapies. By providing clinicians with detailed insights into the spatial arrangement of immune cells and biomarkers within a tumor, Cancer InCITe enables more personalized and effective treatment strategies. The company primarily serves oncology centers and biopharmaceutical partners looking to optimize clinical trial enrollment and therapeutic efficacy.

Therapeutic areas: Oncology
Modalities: Diagnostic testPrecision medicine platform
Industry: Pathology

Beyond the preview

Go deeper on Cancer InCITe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cancer InCITe.

Explore the full profile